Outcomes for Sokal low- and intermediate-risk patients on the ENESTnd trial
| ENESTnd outcomes for Sokal low- and intermediate-risk patients . | Imatinib . | Nilotinib . | |
|---|---|---|---|
| 400 mg daily (n = 283) . | 300 mg twice daily (n = 282) . | 400 mg twice daily (n = 281) . | |
| Low-risk PFS, % | 100 | 96 | 99 |
| Low-risk OS, % | 100 | 97 | 99 |
| Intermediate-risk PFS, % | 88 | 93 | 97 |
| Intermediate-risk OS, % | 89 | 94 | 97 |
| ENESTnd outcomes for Sokal low- and intermediate-risk patients . | Imatinib . | Nilotinib . | |
|---|---|---|---|
| 400 mg daily (n = 283) . | 300 mg twice daily (n = 282) . | 400 mg twice daily (n = 281) . | |
| Low-risk PFS, % | 100 | 96 | 99 |
| Low-risk OS, % | 100 | 97 | 99 |
| Intermediate-risk PFS, % | 88 | 93 | 97 |
| Intermediate-risk OS, % | 89 | 94 | 97 |
There were no significant differences between any groups. Data from Saglio et al11 and Hochhaus et al.14,15